Peng Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peng Xu has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Adam R Abate
3 shared publications- Charles Y. Chiu
University of California, San Francisco, San Francisco
3 shared publications Gordon Murtaugh
3 shared publicationsKrzysztof Langer
3 shared publications- Qin Yan
Department of Pathology, Yale School of Medicine, New Haven, USA
3 shared publications Venice Servellita
3 shared publications
Latest Publications
- 1 November 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (11) , 2015-2033
SUV39H1 Regulates KLF4 and Chromatin Remodeling in Smooth Muscle Cell Phenotypic Plasticity
BACKGROUND: Reversible DNA methylation contributes to vascular smooth muscle cell (VSMC) phenotypic plasticity. This plasticity contributes to vascular growth and remodeling but also underlies pathologies, including intimal hyperplasia. We investigated the role of SUV39H1 (suppressor of variegation 3–9 homolog 1), a histone methyltransferase that generates trimethylation at histone H3 lysine 9 (H3K9me3), a repressive heterochromatin-associated epigenetic mark, in VSMC plasticity. METHODS: We applied knockdown, quantitative polymerase chain reaction, Western blotting, chromatin immunoprecipitation, assay for transposase-accessible chromatin using sequencing, and RNA-sequencing in human coronary artery smooth muscle cells and murine carotid ligation to assess SUV39H1 functions in VSMC plasticity. RESULTS: In normal mouse carotid artery, SUV39H1 and H3K9me3 were markedly increased, while the cognate H3K9me3 demethylase KDM4A (lysine demethylase 4A) rapidly decreased with carotid ligation and neointimal hyperplasia. In human coronary artery smooth muscle cells, SUV39H1 knockdown induced contractile genes, morphology, and contractility but inhibited migration and proliferation. We found that SUV39H1 was required for PDGF (platelet-derived growth factor) induction of KLF4 (Krüppel-like factor 4)—regulating miR143, KLF4 mRNA stability, and promoter accessibility. PDGF-induced SUV39H1 expression and SUV39H1-dependent H3K9me3 modification at contractile gene promoters. SUV39H1 knockdown increased KDM4A expression and binding to contractile promoters, suggesting an opposing regulatory relationship between the H3K9me3 writer and eraser in VSMCs. Chromatin immunoprecipitation assays with SUV39H1 knockdown revealed that SUV39H1 modifies H3K9me3 but also promotes a repressive state (increased 5mC and reduced H3K27Ac [histone K27 acetylation]) at contractile gene promoters. Conversely, SUV39H1 induced an active state at the KLF4 promoter, reducing DNMT1 (DNA methyltransferases 1) recruitment and 5mC (5-methylcytosine) levels. Assay for transposase-accessible chromatin using sequencing revealed that SUV39H1 oppositely modifies chromatin accessibility at phenotype-specific human coronary artery smooth muscle cell promoters genome-wide. Consistently, transcriptomic profiling showed that SUV39H1 and TET2 (Tet methylcytosine dioxygenase 2) oppositely influence SMC gene expression. CONCLUSIONS: We identify SUV39H1 as a potent PDGF-induced epigenetic regulator that promotes KLF4 expression and VSMC dedifferentiation. SUV39H1 regulates dynamic trimethylation at histone H3 lysine 9 in phenotypic switching, regulating mark deposition and the KDM4A demethylase. We report that SUV39H1 coordinately regulates DNA and histone methylation and histone acetylation. This altered chromatin accessibility by a heterochromatin-associated enzyme represents a new mechanism underlying VSMC plasticity.
- 1 November 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (11) , 2015-2033
SUV39H1 Regulates KLF4 and Chromatin Remodeling in Smooth Muscle Cell Phenotypic Plasticity
BACKGROUND: Reversible DNA methylation contributes to vascular smooth muscle cell (VSMC) phenotypic plasticity. This plasticity contributes to vascular growth and remodeling but also underlies pathologies, including intimal hyperplasia. We investigated the role of SUV39H1 (suppressor of variegation 3–9 homolog 1), a histone methyltransferase that generates trimethylation at histone H3 lysine 9 (H3K9me3), a repressive heterochromatin-associated epigenetic mark, in VSMC plasticity. METHODS: We applied knockdown, quantitative polymerase chain reaction, Western blotting, chromatin immunoprecipitation, assay for transposase-accessible chromatin using sequencing, and RNA-sequencing in human coronary artery smooth muscle cells and murine carotid ligation to assess SUV39H1 functions in VSMC plasticity. RESULTS: In normal mouse carotid artery, SUV39H1 and H3K9me3 were markedly increased, while the cognate H3K9me3 demethylase KDM4A (lysine demethylase 4A) rapidly decreased with carotid ligation and neointimal hyperplasia. In human coronary artery smooth muscle cells, SUV39H1 knockdown induced contractile genes, morphology, and contractility but inhibited migration and proliferation. We found that SUV39H1 was required for PDGF (platelet-derived growth factor) induction of KLF4 (Krüppel-like factor 4)—regulating miR143, KLF4 mRNA stability, and promoter accessibility. PDGF-induced SUV39H1 expression and SUV39H1-dependent H3K9me3 modification at contractile gene promoters. SUV39H1 knockdown increased KDM4A expression and binding to contractile promoters, suggesting an opposing regulatory relationship between the H3K9me3 writer and eraser in VSMCs. Chromatin immunoprecipitation assays with SUV39H1 knockdown revealed that SUV39H1 modifies H3K9me3 but also promotes a repressive state (increased 5mC and reduced H3K27Ac [histone K27 acetylation]) at contractile gene promoters. Conversely, SUV39H1 induced an active state at the KLF4 promoter, reducing DNMT1 (DNA methyltransferases 1) recruitment and 5mC (5-methylcytosine) levels. Assay for transposase-accessible chromatin using sequencing revealed that SUV39H1 oppositely modifies chromatin accessibility at phenotype-specific human coronary artery smooth muscle cell promoters genome-wide. Consistently, transcriptomic profiling showed that SUV39H1 and TET2 (Tet methylcytosine dioxygenase 2) oppositely influence SMC gene expression. CONCLUSIONS: We identify SUV39H1 as a potent PDGF-induced epigenetic regulator that promotes KLF4 expression and VSMC dedifferentiation. SUV39H1 regulates dynamic trimethylation at histone H3 lysine 9 in phenotypic switching, regulating mark deposition and the KDM4A demethylase. We report that SUV39H1 coordinately regulates DNA and histone methylation and histone acetylation. This altered chromatin accessibility by a heterochromatin-associated enzyme represents a new mechanism underlying VSMC plasticity.
- Open Access
- 28 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (13) , eads6021
An in vivo screen identifies NAT10 as a master regulator of brain metastasis
Emerging evidence has shown that epigenetic regulation plays a fundamental role in cancer metastasis, the major cause of cancer-related deaths. Here, we conducted an in vivo screen for vulnerabilities of brain metastasis and identified N -acetyltransferase 10 (NAT10) as a driver of brain metastasis. Knockdown of NAT10 restrains cancer cell proliferation and migration in vitro and tumor growth and brain metastasis in vivo. The poorly characterized RNA helicase domain of NAT10 is critical for cell growth in vitro, while both RNA helicase and NAT domains are essential for primary tumor growth and brain metastasis in vivo. Mechanically, NAT10 promotes the expression of 3-phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT1), two enzymes for serine biosynthesis implicated in brain metastasis. Silencing PHGDH or PSAT1 in metastatic breast cancer cells inhibits their growth in the serine/glycine-limited condition, phenocopying the effects of NAT10 depletion. These findings establish NAT10 as a key regulator of brain metastasis and nominate NAT10 as a target for treating metastasis.
- 28 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (13) , eads6021
Open AccessAn in vivo screen identifies NAT10 as a master regulator of brain metastasis
Emerging evidence has shown that epigenetic regulation plays a fundamental role in cancer metastasis, the major cause of cancer-related deaths. Here, we conducted an in vivo screen for vulnerabilities of brain metastasis and identified N -acetyltransferase 10 (NAT10) as a driver of brain metastasis. Knockdown of NAT10 restrains cancer cell proliferation and migration in vitro and tumor growth and brain metastasis in vivo. The poorly characterized RNA helicase domain of NAT10 is critical for cell growth in vitro, while both RNA helicase and NAT domains are essential for primary tumor growth and brain metastasis in vivo. Mechanically, NAT10 promotes the expression of 3-phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT1), two enzymes for serine biosynthesis implicated in brain metastasis. Silencing PHGDH or PSAT1 in metastatic breast cancer cells inhibits their growth in the serine/glycine-limited condition, phenocopying the effects of NAT10 depletion. These findings establish NAT10 as a key regulator of brain metastasis and nominate NAT10 as a target for treating metastasis.
- Open Access
An in vivo screen identifies NAT10 as a master regulator of brain metastasis
Metastasis is the major cause of cancer-related deaths. Emerging evidence has shown that epigenetic regulation plays a fundamental role in cancer metastasis. To better understand the epigenetic regulation of metastasis, we conducted an in vivo shRNA screen for vulnerabilities of brain metastasis and identified N-acetyltransferase 10 (NAT10) as a driver of brain metastasis. Knockdown of NAT10 significantly restrains cancer cell proliferation and migration in vitro , and tumor growth and brain metastasis in vivo . Structure-function analysis of NAT10 showed that its poorly characterized RNA helicase domain is critical for breast cancer cell growth in vitro , while its N-acetyltransferase domain is essential for primary tumor growth and brain metastasis in vivo . Integrative transcriptomic and proteomic analyses revealed key downstream effectors of NAT10, including PHGDH and PSAT1, two catalyzing enzymes for serine biosynthesis implicated in brain metastasis, and HSPA5, known to promote metastasis. We found that distant metastases of breast cancer, especially brain metastases express higher levels of NAT10, PHGDH, PSAT1, and HSPA5. Silencing PHGDH/PSAT1 or HSPA5 in metastatic breast cancer cells inhibits their ability to grow in the serine/glycine-limited condition or migrate, respectively, phenocopying the effects of NAT10 depletion. Moreover, NAT10 promotes the expression of PHGDH, PSAT1, and HSPA5 in its RNA helicase-dependent manner. These findings establish NAT10 as a master regulator of brain metastasis and shed light on the biological functions of its RNA helicase domain, nominating NAT10 as a target for treating metastatic diseases.
Open AccessAn in vivo screen identifies NAT10 as a master regulator of brain metastasis
Metastasis is the major cause of cancer-related deaths. Emerging evidence has shown that epigenetic regulation plays a fundamental role in cancer metastasis. To better understand the epigenetic regulation of metastasis, we conducted an in vivo shRNA screen for vulnerabilities of brain metastasis and identified N-acetyltransferase 10 (NAT10) as a driver of brain metastasis. Knockdown of NAT10 significantly restrains cancer cell proliferation and migration in vitro , and tumor growth and brain metastasis in vivo . Structure-function analysis of NAT10 showed that its poorly characterized RNA helicase domain is critical for breast cancer cell growth in vitro , while its N-acetyltransferase domain is essential for primary tumor growth and brain metastasis in vivo . Integrative transcriptomic and proteomic analyses revealed key downstream effectors of NAT10, including PHGDH and PSAT1, two catalyzing enzymes for serine biosynthesis implicated in brain metastasis, and HSPA5, known to promote metastasis. We found that distant metastases of breast cancer, especially brain metastases express higher levels of NAT10, PHGDH, PSAT1, and HSPA5. Silencing PHGDH/PSAT1 or HSPA5 in metastatic breast cancer cells inhibits their ability to grow in the serine/glycine-limited condition or migrate, respectively, phenocopying the effects of NAT10 depletion. Moreover, NAT10 promotes the expression of PHGDH, PSAT1, and HSPA5 in its RNA helicase-dependent manner. These findings establish NAT10 as a master regulator of brain metastasis and shed light on the biological functions of its RNA helicase domain, nominating NAT10 as a target for treating metastatic diseases.
- Open Access
- 1 September 2023
- Published by IOP Publishing in Biomedical Materials
- Vol. 18 (5) , 059511
Corrigendum: Research on the inhibition for aseptic loosening of artificial joints by Sr-doped calcium polyphosphate (SCPP) in vivo (2021 Biomed. Mater. 16 065017)
- 1 September 2023
- Published by IOP Publishing in Biomedical Materials
- Vol. 18 (5) , 059511
Open AccessCorrigendum: Research on the inhibition for aseptic loosening of artificial joints by Sr-doped calcium polyphosphate (SCPP) in vivo (2021 Biomed. Mater. 16 065017)
- 2 May 2022
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 435, 129042
Effects of microsize on the biocompatibility of UiO67 from protein-adsorption behavior, hemocompatibility, and histological toxicity
- 2 May 2022
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 435, 129042
Effects of microsize on the biocompatibility of UiO67 from protein-adsorption behavior, hemocompatibility, and histological toxicity
- Open Access
- 4 December 2020
- Published by ZappyLab, Inc.
Rapid and high-throughput SARS-CoV-2 screening v3
We have developed a LAMP-based assay for massive COVID screening. The assay includes only two major steps: 1. Mix the sample with the LAMP reagents. 2. Incubate the reaction on a real-time thermocycler and read the signal. There is minimal sample processing. The sample-to-answer turnaround time is about 40min. It can be automated by using the robotic liquid handler for high-throughput screening. The potential capacity is more than thousands of tests per day and yielding results on the same day, which is perfect for the large scale population surveillance.
- 4 December 2020
- Published by ZappyLab, Inc.
Open AccessRapid and high-throughput SARS-CoV-2 screening v3
We have developed a LAMP-based assay for massive COVID screening. The assay includes only two major steps: 1. Mix the sample with the LAMP reagents. 2. Incubate the reaction on a real-time thermocycler and read the signal. There is minimal sample processing. The sample-to-answer turnaround time is about 40min. It can be automated by using the robotic liquid handler for high-throughput screening. The potential capacity is more than thousands of tests per day and yielding results on the same day, which is perfect for the large scale population surveillance.
- Open Access
- 13 November 2020
- Published by ZappyLab, Inc.
Rapid and high-throughput SARS-CoV-2 screening v2
We have developed a LAMP-based assay for massive COVID screening. The assay includes only two major steps: 1. Mix the sample with the LAMP reagents. 2. Incubate the reaction on a real-time thermocycler and read the signal. There is minimal sample processing. The sample-to-answer turnaround time is about 40min. It can be automated by using the robotic liquid handler for high-throughput screening. The potential capacity is more than thousands of tests per day and yielding results on the same day, which is perfect for the large scale population surveillance.
- 13 November 2020
- Published by ZappyLab, Inc.
Open AccessRapid and high-throughput SARS-CoV-2 screening v2
We have developed a LAMP-based assay for massive COVID screening. The assay includes only two major steps: 1. Mix the sample with the LAMP reagents. 2. Incubate the reaction on a real-time thermocycler and read the signal. There is minimal sample processing. The sample-to-answer turnaround time is about 40min. It can be automated by using the robotic liquid handler for high-throughput screening. The potential capacity is more than thousands of tests per day and yielding results on the same day, which is perfect for the large scale population surveillance.
- 7 November 2020
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 12 (48) , 5833-5838
An electroosmotic flow-free two-direction migration strategy enables fast affinity capillary electrophoresis to study the weak interactions between basic peptides and RNA
Two-direction migration enables fast affinity capillary electrophoresis to detect weak and unstable peptide–RNA interactions.
- 7 November 2020
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 12 (48) , 5833-5838
An electroosmotic flow-free two-direction migration strategy enables fast affinity capillary electrophoresis to study the weak interactions between basic peptides and RNA
Two-direction migration enables fast affinity capillary electrophoresis to detect weak and unstable peptide–RNA interactions.
- Open Access
Human Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network
SUMMARY: The COVID-19 pandemic is a widespread and deadly public health crisis. The pathogen SARS-CoV-2 replicates in the lower respiratory tract and causes fatal pneumonia. Although tremendous efforts have been put into investigating the pathogeny of SARS-CoV-2, the underlying mechanism of how SARS-CoV-2 interacts with its host is largely unexplored. Here, by comparing the genomic sequences of SARS-CoV-2 and human, we identified five fully conserved elements in SARS-CoV-2 genome, which were termed as “human identical sequences (HIS)”. HIS are also recognized in both SARS-CoV and MERS-CoV genome. Meanwhile, HIS-SARS-CoV-2 are highly conserved in the primate. Mechanically, HIS-SARS-CoV-2, behaving as virus-derived miRNAs, directly target to the human genomic loci and further interact with host enhancers to activate the expression of adjacent and distant genes, including cytokines gene and angiotensin converting enzyme II ( ACE2 ), a well-known cell entry receptor of SARS-CoV-2, and hyaluronan synthase 2 ( HAS2 ), which further increases hyaluronan formation. Noteworthily, hyaluronan level in plasma of COVID-19 patients is tightly correlated with severity and high risk for acute respiratory distress syndrome (ARDS) and may act as a predictor for the progression of COVID-19. HIS antagomirs, which downregulate hyaluronan level effectively, and 4-Methylumbelliferone (MU), an inhibitor of hyaluronan synthesis, are potential drugs to relieve the ARDS related ground-glass pattern in lung for COVID-19 treatment. Our results revealed that unprecedented HIS elements of SARS-CoV-2 contribute to the cytokine storm and ARDS in COVID-19 patients. Thus, blocking HIS-involved activating processes or hyaluronan synthesis directly by 4-MU may be effective strategies to alleviate COVID-19 progression.
Open AccessHuman Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network
SUMMARY: The COVID-19 pandemic is a widespread and deadly public health crisis. The pathogen SARS-CoV-2 replicates in the lower respiratory tract and causes fatal pneumonia. Although tremendous efforts have been put into investigating the pathogeny of SARS-CoV-2, the underlying mechanism of how SARS-CoV-2 interacts with its host is largely unexplored. Here, by comparing the genomic sequences of SARS-CoV-2 and human, we identified five fully conserved elements in SARS-CoV-2 genome, which were termed as “human identical sequences (HIS)”. HIS are also recognized in both SARS-CoV and MERS-CoV genome. Meanwhile, HIS-SARS-CoV-2 are highly conserved in the primate. Mechanically, HIS-SARS-CoV-2, behaving as virus-derived miRNAs, directly target to the human genomic loci and further interact with host enhancers to activate the expression of adjacent and distant genes, including cytokines gene and angiotensin converting enzyme II ( ACE2 ), a well-known cell entry receptor of SARS-CoV-2, and hyaluronan synthase 2 ( HAS2 ), which further increases hyaluronan formation. Noteworthily, hyaluronan level in plasma of COVID-19 patients is tightly correlated with severity and high risk for acute respiratory distress syndrome (ARDS) and may act as a predictor for the progression of COVID-19. HIS antagomirs, which downregulate hyaluronan level effectively, and 4-Methylumbelliferone (MU), an inhibitor of hyaluronan synthesis, are potential drugs to relieve the ARDS related ground-glass pattern in lung for COVID-19 treatment. Our results revealed that unprecedented HIS elements of SARS-CoV-2 contribute to the cytokine storm and ARDS in COVID-19 patients. Thus, blocking HIS-involved activating processes or hyaluronan synthesis directly by 4-MU may be effective strategies to alleviate COVID-19 progression.
- Open Access
- 8 September 2020
- Published by ZappyLab, Inc.
Rapid and high-throughput SARS-CoV-2 screening without sample processing v1
We have developed a LAMP-based assay for massive COVID screening. The assay includes only two major steps: 1. Mix the sample with the LAMP reagents. 2. Incubate the reaction on a real-time thermocycler and read the signal. There is no sample processing (without adding any lysis buffer or reagents). The sample-to-answer turnaround time is about 30min. It can be automated by using the robotic liquid handler for high-throughput screening. The potential capacity is more than thousands of tests per day and yielding results on the same day, which is perfect for the large scale population surveillance.
- 8 September 2020
- Published by ZappyLab, Inc.
Open AccessRapid and high-throughput SARS-CoV-2 screening without sample processing v1
We have developed a LAMP-based assay for massive COVID screening. The assay includes only two major steps: 1. Mix the sample with the LAMP reagents. 2. Incubate the reaction on a real-time thermocycler and read the signal. There is no sample processing (without adding any lysis buffer or reagents). The sample-to-answer turnaround time is about 30min. It can be automated by using the robotic liquid handler for high-throughput screening. The potential capacity is more than thousands of tests per day and yielding results on the same day, which is perfect for the large scale population surveillance.